How Reprogrammed Stem Cells Could Change Type 1 Diabetes
A remarkable step toward replacing the insulin-making cells the disease destroys
For people living with Type 1 diabetes, managing the condition can become part of almost every hour of the day.
Blood glucose needs to be monitored. Insulin has to be delivered. Meals, exercise, illness and stress can all affect glucose levels. Modern tools such as continuous glucose monitors and automated insulin-delivery systems have made that routine easier for many people, but Type 1 diabetes still requires constant attention.
That is why recent progress in stem-cell research has attracted so much attention.
Scientists are now testing ways to replace the insulin-producing pancreatic cells destroyed by Type 1 diabetes. In one remarkable 2024 case, researchers in China reported that a woman with Type 1 diabetes began producing insulin after receiving islet cells created from her own reprogrammed cells. The report was an important proof of concept—but it was a single-patient study, not yet a widely available cure.
More recent clinical research has added to the excitement, showing that stem-cell-derived islet cells can survive after transplantation and produce insulin in people with Type 1 diabetes.
How can ordinary cells become insulin-producing cells?
The basic idea sounds almost futuristic.
Researchers can take mature human cells and use cellular reprogramming techniques to return them to a stem-cell-like state. These cells can then be guided through a carefully controlled laboratory process to develop into pancreatic islet cells, including insulin-producing beta cells.
The goal is straightforward: replace the cells that Type 1 diabetes has destroyed with new cells capable of sensing glucose and releasing insulin.
In the 2024 Chinese study, researchers used chemically induced pluripotent stem cells derived from the patient’s own tissue. The resulting islet cells were transplanted into the abdominal region rather than delivered through the liver’s portal vein, which is commonly used for conventional islet transplantation. The patient subsequently achieved insulin independence during follow-up.
That does not mean scientists have solved Type 1 diabetes. It means they have demonstrated something extremely important: replacement insulin-producing tissue can potentially be created from a patient’s own cells and function inside the body.
Why using a patient’s own cells matters
Traditional islet transplantation uses insulin-producing cells obtained from organ donors.
This approach can work. In fact, the U.S. Food and Drug Administration approved the donor-derived islet therapy Lantidra in 2023 for certain adults with Type 1 diabetes who experience repeated severe hypoglycemia despite intensive diabetes management. However, the therapy requires immunosuppressive medication, and donor tissue is inherently limited.
Stem-cell technology could eventually address one of those major limitations.
In theory, cells could be produced in laboratories at a much larger scale instead of relying entirely on deceased donors. Using a patient’s own cells could also reduce some problems associated with immune compatibility.
But there is an important complication: Type 1 diabetes is an autoimmune disease.
The original disease does not simply remove beta cells. The immune system is involved in destroying them. So even if scientists successfully replace those cells, researchers still have to determine how to protect the new cells from future immune attack.
That is one of the biggest challenges standing between an impressive experiment and a dependable long-term treatment.
The latest research is encouraging—but still early
The field has moved beyond isolated laboratory experiments.
In a 2025 New England Journal of Medicine study of a stem-cell-derived islet therapy called zimislecel, 14 participants had evidence that the transplanted cells engrafted and began producing insulin. Among 12 participants receiving a full dose, all were free of severe hypoglycemic events and had glycated hemoglobin below 7% during the reported period; 10 of those 12 participants were insulin-independent at one year.
Those results are significant, but the study was small and follow-up was limited. Participants also received immunosuppressive therapy.
That last point is crucial.
Researchers still need to establish how long the transplanted cells will continue functioning, how safely the treatment can be delivered, whether immune rejection can be prevented without substantial immunosuppression and whether the approach can eventually be scaled to large numbers of patients.
What does this mean for people living with Type 1 diabetes today?
For now, stem-cell therapy should be viewed as promising research—not a replacement for established diabetes care.
Insulin remains essential for people with Type 1 diabetes unless a specialist has specifically determined that another approved treatment or clinical therapy is appropriate.
At the same time, diabetes technology continues to improve. Continuous glucose monitors, insulin pumps and automated insulin-delivery systems can help people manage glucose more effectively and reduce some of the burden of day-to-day decision-making.
The goal of regenerative medicine is different. Rather than simply improving the delivery of insulin from outside the body, researchers are trying to restore the body’s ability to make insulin itself.
The road ahead
The most exciting part of this research may not be the idea of “no more injections” tomorrow.
It is the possibility that medicine is beginning to move from managing the consequences of cell loss to replacing the cells themselves.
The early results are encouraging, but headlines about a “cure” can create unrealistic expectations. One patient’s success cannot establish that a treatment is safe, permanent or suitable for everyone.
Larger clinical trials and longer follow-up are still needed.
For now, the message is hopeful but measured: scientists have shown that stem-cell-derived insulin-producing cells can function in people with Type 1 diabetes. The challenge now is turning that breakthrough into a treatment that is safe, durable, accessible and effective for many more people.
For anyone living with Type 1 diabetes, that future may still be some distance away.
But for the first time, researchers are getting closer to something that once seemed extraordinarily difficult: helping the body make its own insulin again.
Photo by Jane Korsak on Unsplash
About Wellcore Weekly: Wellcore Weekly covers health, wellness, nutrition, sleep, fitness, and medical research with timely, easy-to-understand updates for everyday readers.
